Sermorelin has more human data behind it than most compounded peptides sold online today. That data is also thinner than the marketing around it suggests: three published studies, the largest with nineteen people, running for weeks rather than years.
The honest read is not that sermorelin doesn’t work on the growth hormone axis. It does, reliably, in the trials that exist. The honest read is that nobody has tested whether raising GH and IGF-1 this way changes anything a patient would notice a decade later.
What three human studies found
Sermorelin is built on the growth hormone releasing hormone (1-29) fragment, the truncated form of GHRH that researchers use as their potency reference when they engineer newer, more potent analogues. Izdebski and colleagues’ structure-activity work measured every superactive candidate against hGH-RH-(1-29)-NH2 as the baseline [1]. Sermorelin is close to the natural signal itself, shortened to the 29 residues that retain activity, rather than a novel molecule dressed up with a brand name.
Three published human studies give sermorelin, or its direct analogues, an actual evidence base:
The three human sermorelin studies
Study | Design | Participants | Duration |
|---|---|---|---|
Khorram, Laughlin and Yen, 1997 | Randomized, placebo-controlled | 19 adults, ages 55 to 71 | 16 weeks |
Corpas and colleagues, 1992 | Dose comparison, no placebo arm | 10 old men | Two 14-day periods |
Wilton and colleagues, 1993 | Dose-response, pharmacokinetic | Healthy men, single doses | Single-dose administration |
Everything published to date.
Khorram, Laughlin and Yen ran the strongest of the three: a randomized, placebo-controlled trial in 19 adults aged 55 to 71. Nightly subcutaneous injections of a GHRH(1-29) analogue for 16 weeks significantly raised nocturnal growth hormone and IGF-1 compared with placebo [2].
Corpas and colleagues took a narrower question. Ten old men received sermorelin at 0.5 mg or 1 mg subcutaneously, twice daily, across two 14-day dosing periods. Only the higher dose raised 24-hour GH and IGF-1 to the levels seen in young men [3].
10 old men in the longest-running sermorelin dosing study on record PMID 1379256
Wilton and colleagues asked a different question entirely: how much sermorelin, given as a single intravenous or intranasal bolus, is needed to trigger a GH response. That’s a pharmacokinetic dose-response study rather than a treatment trial [4], and the three of them together make up the entire published human trial record for sermorelin.
Interventional data, and where its authority ends
All three studies are interventional. Researchers gave sermorelin, or a close analogue, and measured what happened next, rather than watching people who happened to already be using it. Khorram, Laughlin and Yen’s trial was randomized and placebo-controlled [2], the design that lets you say the GH and IGF-1 changes were caused by the injections, not by chance or by whatever else was happening in a participant’s life that month.
That authority is narrow. A causal claim about hormone levels over 16 weeks says nothing about whether those hormone changes translate into anything durable. No published randomized trial has tested whether sermorelin changes fracture risk, cardiovascular events, or mortality. The question has not been asked, at any scale.
What the evidence cannot say: three small studies establish that sermorelin raises GH and IGF-1 in the short term. None of them, and no trial anywhere, has tested whether that matters for a hard outcome years later.
Corpas’ study is worth a second look, because it complicates the tidy “these are all placebo-controlled trials” story you’ll read elsewhere. It didn’t use a placebo arm at all. Participants alternated between treatment doses with a washout period in between [3], a weaker design than Khorram’s. Treating every sermorelin study as equally rigorous overstates what a third of the evidence base did.
The receptor mechanism is solid. The safety logic is a hypothesis
Sermorelin knocks on one specific receptor; the pituitary does the rest.
Here the biochemistry isn’t in dispute. Sermorelin binds the GHRH receptor on pituitary somatotroph cells, which triggers synthesis and pulsatile release of endogenous growth hormone, rather than supplying growth hormone directly the way recombinant hGH does. Petersenn and Schulte’s review traces the receptor from its cloning to its signaling pathway in detail [5].
The safety argument built on top of that mechanism is softer. Sigalos and Pastuszak note that GH secretagogues work upstream of the pituitary and remain subject to the body’s own negative feedback, which is believed to prevent the supra-therapeutic GH spikes seen with direct GH administration [6].
That’s a plausible mechanism. It is also, as stated, a belief rather than a demonstrated clinical advantage. Nobody has run a head-to-head human trial comparing sermorelin to recombinant GH on long-term adverse effects to confirm that preserved feedback protects patients any better in practice.
A more familiar corner of endocrinology makes the same distinction. A sulfonylurea prods the pancreas into releasing more of its own insulin; injected insulin replaces it outright.
One works through an existing regulatory loop, the other overrides it. That “work through the loop” approach really does carry a different risk profile in diabetes care, but it took decades of outcome trials to confirm that clinically. Sermorelin has had none.
Dosing, as researchers used it
None of this is a recommendation. It’s what appeared in the published record.
Corpas, 1992: 0.5 mg or 1 mg subcutaneously, twice daily, for 14 days at a time. Only the 1 mg dose moved GH and IGF-1 [3].
Wilton, 1993: A single intravenous or intranasal bolus, used purely to map the dose-response curve rather than to treat anyone over time [4]. Diagnostic-style stimulation testing and multi-week treatment dosing are different protocols, and conflating the two is a common error in how sermorelin gets described online.
No published trial has followed sermorelin use for longer than several months. What years of off-label, compounded use does to a person is simply unmeasured.
Side effects, and who’s allowed to sell this
Dominikowski and colleagues’ review of GH-IGF-1-axis peptides sold for self-administration, sermorelin included, lists injection-site reactions alongside endocrine and metabolic disturbances (changes in prolactin, cortisol, and glucose regulation) among the reported adverse effects [7]. That’s a narrower, more clinical list than “mild and self-limited,” the phrase you’ll find on sales pages.
Sourcing matters here. Mendias and Awan’s review places sermorelin among peptides sold outside FDA regulatory oversight, in contrast to an FDA-approved GHRH analogue like tesamorelin [8]. Anyone buying sermorelin today is buying a compounded product rather than an approved drug.
For the regulatory mechanics of how that came to be, Sermorelin’s FDA and 503A status covers the question in full. It’s a separate question from whether the compound does anything on the growth hormone axis, and conflating the two is how a pharmacology question turns into a legal one.
Where sermorelin sits against tesamorelin and ipamorelin
Sermorelin is not the only GHRH-pathway peptide with a research record, and it is not the best-studied one. Dominikowski and colleagues’ review stratifies GH-axis peptides sold for self-administration on a scale running from regulatory-grade randomized trial data down to a complete absence of human studies [7]. Sermorelin sits well below the top of that scale. Tesamorelin sits well above it.
How many people were studied
Corpas 1992 (sermorelin): 10
Khorram 1997 (sermorelin): 19
Tesamorelin extension trial: 410
Sermorelin's evidence base against tesamorelin's pivotal extension trial.
Falutz and colleagues randomized 410 HIV patients with abdominal fat accumulation to tesamorelin or placebo, double-blind, and followed them for up to a year [9]. That is a different order of evidence than a ten-person, two-week dosing study. What Is Tesamorelin? A Straight Answer for Researchers covers that trial record on its own.
Ipamorelin makes an instructive contrast from the other direction. It works through the ghrelin receptor rather than the GHRH receptor, and it has even less independent human trial support than sermorelin, despite near-identical marketing. Sitting near a well-studied hormone pathway doesn’t make a compound well studied in its own right.
What follows from this, practically speaking
If you’re trying to decide what to make of sermorelin, the evidence supports a narrow set of statements and nothing more:
It measurably raises growth hormone and IGF-1 over weeks to months in older adults, at doses researchers have published and tested.
It does this through a receptor mechanism mapped down to the receptor’s structure and signaling pathway, well understood at the molecular level.
It has not been tested against any outcome that would matter to a patient over years: strength, fracture risk, disease incidence, mortality.
What’s sold today is a compounded product made outside the regulatory oversight that governs an approved drug.
Everything past that list is extrapolation. It gets sold with far more confidence than any of these three trials earned.
The bottom line
Sermorelin’s evidence base is real but small: three human studies, the largest randomized and placebo-controlled, the others closer to dose-finding pharmacology than treatment trials. Within that limited scope, sermorelin reliably raises growth hormone and IGF-1. Outside that scope, on the questions people buy this peptide to answer (muscle, fat loss, longevity, recovery) there is no trial evidence at all.
Bottom line: the receptor biology is solid, the short-term hormone response is real and replicated twice, and everything past that point is extrapolation sold as certainty.
That gap between what three small studies proved and what the sales copy promises is a reason to stop treating a 16-week hormone reading as a verdict on a decade of use. Read the trials for what they measured. The marketing implies a great deal more than that.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone.. Proceedings of the National Academy of Sciences of the United States of America, 1995.
Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.. The Journal of clinical endocrinology and metabolism, 1997.
Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.. The Journal of clinical endocrinology and metabolism, 1992.
Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration.. Acta paediatrica (Oslo, Norway : 1992). Supplement, 1993.
Structure and function of the growth-hormone-releasing hormone receptor.. Vitamins and hormones, 2000.
The Safety and Efficacy of Growth Hormone Secretagogues.. Sexual medicine reviews, 2018.
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.. Frontiers in endocrinology, 2026.
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports medicine (Auckland, N.Z.), 2026.
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.. AIDS (London, England), 2008.
